Oak Thistle LLC Acquires New Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Oak Thistle LLC bought a new position in Axon Enterprise, Inc. (NASDAQ:AXON) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,091 shares of the biotechnology company’s stock, valued at approximately $341,000.

Several other hedge funds have also recently made changes to their positions in AXON. ICA Group Wealth Management LLC bought a new position in Axon Enterprise in the 4th quarter worth approximately $26,000. Trivant Custom Portfolio Group LLC purchased a new position in shares of Axon Enterprise in the first quarter valued at $31,000. First PREMIER Bank bought a new stake in shares of Axon Enterprise during the 1st quarter valued at $33,000. BKM Wealth Management LLC purchased a new stake in Axon Enterprise during the 4th quarter worth about $32,000. Finally, Rise Advisors LLC boosted its stake in Axon Enterprise by 49.0% in the 1st quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 47 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Jeri Williams sold 308 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $310.07, for a total value of $95,501.56. Following the transaction, the director now owns 1,607 shares in the company, valued at $498,282.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, President Joshua Isner sold 44,000 shares of the company’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $309.96, for a total transaction of $13,638,240.00. Following the completion of the sale, the president now directly owns 275,843 shares in the company, valued at approximately $85,500,296.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeri Williams sold 308 shares of the company’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $310.07, for a total transaction of $95,501.56. Following the sale, the director now owns 1,607 shares of the company’s stock, valued at $498,282.49. The disclosure for this sale can be found here. Insiders have sold 89,447 shares of company stock valued at $27,684,677 in the last ninety days. Company insiders own 5.70% of the company’s stock.

Axon Enterprise Price Performance

AXON stock opened at $289.21 on Tuesday. The firm has a market cap of $21.83 billion, a P/E ratio of 84.56 and a beta of 0.95. The firm’s fifty day moving average is $295.16 and its 200 day moving average is $285.51. Axon Enterprise, Inc. has a 52 week low of $175.37 and a 52 week high of $329.87. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.55 and a current ratio of 2.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Friday, May 10th. The biotechnology company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.20. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. The firm had revenue of $460.74 million for the quarter, compared to analysts’ expectations of $441.57 million. During the same period last year, the firm earned $0.51 earnings per share. The company’s revenue for the quarter was up 34.3% compared to the same quarter last year. Research analysts predict that Axon Enterprise, Inc. will post 2.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

AXON has been the topic of a number of analyst reports. JPMorgan Chase & Co. upped their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a report on Thursday, April 11th. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a research report on Wednesday, April 24th. StockNews.com cut Axon Enterprise from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. Craig Hallum raised their price target on Axon Enterprise from $325.00 to $370.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Finally, Morgan Stanley lifted their price target on Axon Enterprise from $285.00 to $310.00 and gave the company an “equal weight” rating in a research report on Friday, April 26th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $335.27.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.